Literature DB >> 8494788

Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells.

M Shichiri1, K D Hanson, J M Sedivy.   

Abstract

The relative contributions of deregulation versus high level expression of the c-myc gene to malignant transformation are not clear. To investigate the effects of subtle perturbations in c-myc expression on normal cellular physiology, we isolated cell lines with one c-myc gene copy disrupted by targeted homologous recombination. The heterozygous cell lines were further modified by introducing a c-myc transgene expressed 4-fold above the normal diploid level. During exponential growth, heterozygous cells expressed c-Myc mRNA at approximately 50% of the level found in diploid cells, resulting in a slower growth rate. The c-myc transgene reversed the growth defect and accelerated growth relative to diploid cells. Serum deprivation of transgene-expressing cells caused a fraction of the culture to undergo apoptosis. After an initial wave of apoptosis, the remainder of the culture successfully entered Go. Transgene mRNA continued to be constitutively expressed in quiescent cells, but c-Myc protein was not detectable. During the G0 to G1 transition, heterozygous cells induced c-myc expression with normal kinetics, but levels throughout the time course were consistently at least 50% lower than those in diploid cells. The reduction in c-myc expression was correlated with a 3-4-h delay in entry into S phase. The presence of the transgene, which was expressed constitutively throughout the G0 to G1 transition, reversed the delay but did not further accelerate entry into S phase. Our results show that even small perturbations in c-myc expression cause changes in the proliferative status of cells and thus argue that the natural regulation patterns of the gene are crucial for the maintenance of normal cellular physiology.

Entities:  

Mesh:

Year:  1993        PMID: 8494788

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  29 in total

1.  Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression.

Authors:  L He; J Liu; I Collins; S Sanford; B O'Connell; C J Benham; D Levens
Journal:  EMBO J       Date:  2000-03-01       Impact factor: 11.598

Review 2.  Analysis of cell cycle phases and progression in cultured mammalian cells.

Authors:  Christoph Schorl; John M Sedivy
Journal:  Methods       Date:  2007-02       Impact factor: 3.608

Review 3.  G1 to S phase cell cycle transition in somatic and embryonic stem cells.

Authors:  Irina Neganova; Majlinda Lako
Journal:  J Anat       Date:  2008-07       Impact factor: 2.610

4.  Antiproliferative and c-myc mRNA suppressive effect of tranilast on newborn human vascular smooth muscle cells in culture.

Authors:  K Miyazawa; S Hamano; A Ujiie
Journal:  Br J Pharmacol       Date:  1996-06       Impact factor: 8.739

Review 5.  FUBP/KH domain proteins in transcription: Back to the future.

Authors:  Leonie M Quinn
Journal:  Transcription       Date:  2017-02-16

6.  Growth-promoting and tumourigenic activity of c-Myc is suppressed by Hhex.

Authors:  V Marfil; M Blazquez; F Serrano; J V Castell; R Bort
Journal:  Oncogene       Date:  2014-09-15       Impact factor: 9.867

7.  Heterogeneous nuclear ribonucleoprotein K is a transcription factor.

Authors:  E F Michelotti; G A Michelotti; A I Aronsohn; D Levens
Journal:  Mol Cell Biol       Date:  1996-05       Impact factor: 4.272

8.  Analysis of biological selections for high-efficiency gene targeting.

Authors:  K D Hanson; J M Sedivy
Journal:  Mol Cell Biol       Date:  1995-01       Impact factor: 4.272

9.  Differences in the molecular structure of c-myc-activating recombinations in murine plasmacytomas and precursor cells.

Authors:  J R Müller; M Potter; S Janz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-06       Impact factor: 11.205

10.  Notch signaling defects in NK cells in patients with cancer.

Authors:  Gulnur K Zakiryanova; Elena Kustova; Nataliya T Urazalieva; Emile T Baimukhametov; Valeriy A Makarov; Gulmariya M Turaly; Galina V Shurin; Zarema M Biyasheva; Narymzhan N Nakisbekov; Michael R Shurin
Journal:  Cancer Immunol Immunother       Date:  2020-10-21       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.